First approvals for Amgen's Prolia
This article was originally published in Scrip
Amgen's RANK ligand targeting antibody Prolia (denosumab) has been approved in its first market, the EU. Roll out of the product will begin with a launch in the UK next week, where it will cost £183 per injection (one injection is needed every six months); other early markets are expected to be Germany and the Nordic countries.
You may also be interested in...
Another disappointment for irritable bowel syndrome therapies as Urovant Science’s vibegron fails in a Phase II trial, likely spelling the end for the investigational indication.
Pharma pays $50m up front to tap insitro’s in vitro modeling technology, partners with Sensyne Health in blood disorders. Lilly’s COVID-19 partner AbCellera teams with Kodiak in ophthalmology R&D.
Another failed study in Duchenne muscular dystrophy spells the end for edasalonexent and possibly the firm.